Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYang LiuAPAndrew S. ParkDBDaniela Benítez-Cano

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals real-world treatment patterns in MCL patients, indicating significant safety concerns associated with existing therapies.

Key Points

  • To describe treatment patterns and safety profiles among patients diagnosed with mantle cell lymphoma.
  • Retrospective cohort study of adults diagnosed with MCL from 2013-2023
  • Data sourced from Optum Market Clarity with de-identified patient information
  • Treatment outcomes evaluated according to NCCN guidelines
  • 1,936 patients analyzed, predominantly male (71%) and Caucasian (81%)
  • Majority treated with Rituximab-based regimens (89%)
  • 66% developed any infection post-treatment, indicating significant safety issues

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d27fhttps://doi.org/10.1182/blood-2025-1795
View Full Paper
Ask AI
Bookmark
Share